Neoleukin Therapeutics Logo

Designing De Novo Protein Immunotherapies Using Ground-Breaking Computational Methods

Neoleukins represent a novel class of drugs that precisely regulate immune pathways as potential treatments for human diseases. Sophisticated technology is used to create new protein sequences that are more potent, stable, and selective than natural or modified proteins. The scientific founders are among the world's leaders in the emerging field of de novo protein design.

As seen in Nature and in Nature News and Views

To learn more:

Jonathan G Drachman, MD
Jonathan G Drachman, MD
Chief Executive Officer
Daniel-Adriano Silva, PhD
Daniel-Adriano Silva, PhD
Co-Founder
Umut Y Ulge, MD, PhD
Umut Y Ulge, MD, PhD
VP, Translational Medicine
Carl D Walkey, PhD
Carl D Walkey, PhD
Co-Founder
Alfredo Quijano Rubio, BSc
Alfredo Quijano Rubio, BSc
Co-Founder